Prostate-Specific Membrane Antigen (PSMA)

August 9, 2018August 9, 2018

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

News

A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. ... Read more

July 26, 2018

Long-term ADT Use Can Diminish Tumors’ Visibility on Scans, Study Reports

News

Long-term use of androgen deprivation therapy (ADT) can make prostate cancer lesions difficult or impossible to see on some imaging scans, even in tumors that continue to grow, a new study shows. ... Read more

December 13, 2017

PET Scans Help Identify Certain PC Patients Who May Benefit from Salvage Radiation Therapy

News

A recent study-based article demonstrates that prostate-specific membrane antigen (PSMA)-PET scans can identify prostate cancer patients likely to benefit from salvage radiation therapy (SRT) after a radical prostatectomy, and that ... Read more

June 20, 2017

Targeted Photodynamic Therapy May Help in Treatment of Prostate Cancer, Study Suggests

News

Targeted photodynamic therapy may be a potential approach to treat prostate cancer, according to the results of a new preclinical study. The study, titled “Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer ... Read more

April 18, 2017

CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences

News

The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business ... Read more

January 23, 2017

Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers

News

Telix Pharmaceuticals and Atlab Pharma are working together to develop and possibly market huJ591, a monoclonal antibody to be used in radioimmunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more